Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Recruiting	Phase 2	2025-11-17		NCT05973864

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
UNICANCER	111

20 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre François Baclesse	Caen	France	23
Centre Georges-François Leclerc	Dijon	France	7
Centre Hospitalier de la Côte Basque	Bayonne	France	14
Centre Léon Bérard	Lyon	France	50
Centre Oscar Lambret	Lille	France	61
Centre Paul Strauss	Strasbourg	France	27
CHD Vendee	La Roche-sur-Yon	France	3
CHU Amiens Picardie_Site Sud	Amiens	France	2
CHU Bretonneau	Tours	France	7
CHU Jean Minoz	Besançon	France	1
Clinique de la Croix du Sud	Quint-Fonsegrives	France	6
Clinique Mutualiste de l'Estuaire	Saint-Nazaire	France	8
Institut Claudius Regaud, IUCT Oncopole	Toulouse	France	1
Institut Curie	Saint-Cloud	France	19
Institut Curie	Paris	France	81
Institut de Cancérologie de Lorraine	Vandœuvre-lès-Nancy	France	27
Institut Godinot	Reims	France	12
Institut Paoli-Calmettes	Marseille	France	35
Institut Sainte Catherine	Avignon	France	29
Polyclinique Bordeaux Nord Aquitaine	Bordeaux	France	8

Clinical trials